Remove sanofis-quiet-sarclisa-chalks-first-class-win-eyes-first-line-multiple-myeloma-nod
article thumbnail

Sanofi's quiet Sarclisa chalks up a first-in-class win with eyes on a first-line multiple myeloma nod

Fierce Pharma

In the currently mismatched CD38 antibody race, Sanofi’s Sarclisa has delivered a pivotal trial win, which might help the lagging follower level the playing field a little. |

243
243